Artiva Biotherapeutics Inc 2026年季度报告

(Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the transition period fromtoCommission file number: 001-42179 Artiva Biotherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware(State or other jurisdiction ofincorporation or organization) 5505 Morehouse Drive, Suite 100San Diego CA 92121(858) 267-4467(Address including zip code, and telephone number including area code, of registrant’s principal executive offices) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to filesuch reports); and (2) has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, everyInteractive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) duringthe preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or asmaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” inRule 12b-2 of the Exchange Act. (Check one): Large accelerated filer☐Non-accelerated filer☒Emerging growth company☒ Smaller reporting company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition periodfor complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes☐No☒As of April 30, 2026, the registrant had 24,716,672 shares of common stock outstanding. Artiva Biotherapeutics, Inc.Table of Contents PagePart I - Financial Information5Item 1. Financial Statements (Unaudited)5Condensed Balance Sheets5Condensed Statements of Operations and Comprehensive Loss6Condensed Statements of Stockholders’ Equity7Condensed Statements of Cash Flows8Notes to Condensed Financial Statements9Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations22Item 3. Quantitative and Qualitative Disclosures About Market Risk33Item 4. Controls and Procedures33Part II - Other Information34Item 1. Legal Proceedings34Item 1A. Risk Factors34Item 2. Unregistered Sales of Equity Securities and Use of Proceeds92Item 3. Defaults Upon Senior Securities92Item 4. Mine Safety Disclosures92Item 5. Other Information93Item 6. Exhibits94Signatures95 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (Quarterly Report) contains forward-looking statements about us and our industry thatinvolve substantial risks and uncertainties. All statements other than statements of historical facts contained in this QuarterlyReport, including statements regarding future events, our business strategy, and the plans and objectives of management for futureoperations, are forward-looking statements. We have based these forward-looking statements largely on our current expectationsand projections. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,”“believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,”“should,” “target,” “will,” or “would,” or the negative of these words or other similar terms or expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results,performance or achievements to be materially different from any future results, performance or achievements expressed or impliedby the forward-looking statements. Forward-looking statements include, but are not limited to, statements about: •the success, cost, timing and potential indications of our product development activities and clinical trials, including theongoing clinical trials of AlloNK;•the timing of our planned Investigational New Drug application (IND) submissions to the United States Food and DrugAdministration (FDA) for our product candidates, including AlloNK;•the timing of the initiation, enrollment and completion of planned clinical trials;•the ability to obtain regulatory approval for our manufacturing facility in San Diego, California and the cost and timingassociated therewith;•our ability to obtain and maintain regulatory approval